TY - JOUR
T1 - Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache
AU - Bach, F W
AU - Langemark, M
AU - Ekman, R
AU - Rehfeld, J F
AU - Schifter, S
AU - Olesen, J
PY - 1994/8
Y1 - 1994/8
N2 - In lumbar cerebrospinal fluid (CSF) obtained from patients with chronic tension-type headache (CTH), the concentrations of beta-endorphin, met-enkephalin, dynorphin, cholecystokinin (CCK), calcitonin gene-related peptide (CGRP), and somatostatin were measured before and after 8 weeks of treatment with sulpiride or paroxetine. We previously reported higher than normal met-enkephalin concentrations in CTH. The present study reveals normal basal concentrations of CCK, CGRP and somatostatin and slightly decreased dynorphin in the same patients. Treatment with sulpiride or paroxetine did not change the concentration of any of the neuropeptides measured. These data suggest central changes in opioid systems but not in other peptide systems (CCK, CGRP, somatostatin) involved in nociceptive processing at the level of the spinal cord dorsal horn/nucleus caudalis of the trigeminal nerve in CTH. Such central changes might be pathophysiologically important or merely secondary to other more important occurrences. The lack of changes in neuropeptide concentrations during drug treatment makes planning of studies involving CSF analysis easier, but also limits the probability of obtaining information on specific neuropeptide systems through CSF analysis.
AB - In lumbar cerebrospinal fluid (CSF) obtained from patients with chronic tension-type headache (CTH), the concentrations of beta-endorphin, met-enkephalin, dynorphin, cholecystokinin (CCK), calcitonin gene-related peptide (CGRP), and somatostatin were measured before and after 8 weeks of treatment with sulpiride or paroxetine. We previously reported higher than normal met-enkephalin concentrations in CTH. The present study reveals normal basal concentrations of CCK, CGRP and somatostatin and slightly decreased dynorphin in the same patients. Treatment with sulpiride or paroxetine did not change the concentration of any of the neuropeptides measured. These data suggest central changes in opioid systems but not in other peptide systems (CCK, CGRP, somatostatin) involved in nociceptive processing at the level of the spinal cord dorsal horn/nucleus caudalis of the trigeminal nerve in CTH. Such central changes might be pathophysiologically important or merely secondary to other more important occurrences. The lack of changes in neuropeptide concentrations during drug treatment makes planning of studies involving CSF analysis easier, but also limits the probability of obtaining information on specific neuropeptide systems through CSF analysis.
KW - Adult
KW - Aged
KW - Basal Metabolism
KW - Calcitonin Gene-Related Peptide/cerebrospinal fluid
KW - Cholecystokinin/cerebrospinal fluid
KW - Chronic Disease
KW - Dopamine D2 Receptor Antagonists
KW - Dynorphins/cerebrospinal fluid
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Neuropeptides/cerebrospinal fluid
KW - Paroxetine/pharmacology
KW - Somatostatin/cerebrospinal fluid
KW - Sulpiride/pharmacology
KW - Tension-Type Headache/cerebrospinal fluid
UR - https://www.scopus.com/pages/publications/0028107876
U2 - 10.1016/0143-4179(94)90053-1
DO - 10.1016/0143-4179(94)90053-1
M3 - Journal article
C2 - 7991067
SN - 0143-4179
VL - 27
SP - 129
EP - 136
JO - Neuropeptides
JF - Neuropeptides
IS - 2
ER -